Crescent Pharma Limited

Private and voluntary organisations · Private limited company

Pin Request correction

First report 9 Jan 2015•Latest report 9 Jan 2015

Reports, concerns and published responses

Reports over time

Reports naming this recipient by issue year.

* 2026 is projected from reports observed to 7 Sep 2026.

Reports
1

Naming this recipient

Published responses
100%

Found for named reports

Concerns addressed
1

Across all linked responses

Stated actions
2

Described in responses

Concerns and recipient responses

Statements from Crescent Pharma Limited linked to the concerns in each report. Select any concern, action or position to view the source wording.

  1. Birmingham and Solihull

    AI-generated summary

    Annette Charlton · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Annette Charlton, who had emphysema and lung fibrosis requiring continuous oxygen therapy, was dispensed Naproxen instead of prescribed antibiotics and died on 28 September 2014. The principal concern was that medication manufacturers used almost identical packaging, which was considered likely to contribute to dispensing errors and potentially patient deaths.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below. The report was sent to Crescent Pharma Limited; that does not assign responsibility.

    PFD Monitor interpretation

    Almost identical medication boxes

    Wider context from the report

    “(1) Manufacturers are able to produce medication in almost identical boxes which is very likely to contribute to dispensing errors and potentially patient deaths. ”
    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Revise product artwork to minimise pharmacist dispensing errors caused by failure to verify product identity.

    Verbatim wording from the response

    “Crescent are therefore committed to revising product artwork to help minimise pharmacist error, caused by the failure to verify product identity during dispensing.”

    Source location

    2015-0009-Response-by-Crescent-Pharma-Limted
    Page 1 · response
    Published 9 January 2015

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Meet with the MHRA to discuss packaging redesign and colour differentiation between products and strengths.

    Verbatim wording from the response

    “Regarding the issue of packaging similarity, Crescent has scheduled a meeting with the MHRA on the 20th January 2015 to discuss packaging redesign and use of colour to differentiate between different products and strengths, after their request to do so in May 2014.”

    Source location

    2015-0009-Response-by-Crescent-Pharma-Limted
    Page 1 · response
    Published 9 January 2015

    Open published response
Back to top

Information checked against published PFD reports and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Data last updated 7 September 2026